Denali Therapeutics DNLI Stock
Denali Therapeutics Price Chart
Denali Therapeutics DNLI Financial and Trading Overview
| Denali Therapeutics stock price | 18.89 USD |
| Previous Close | 19.73 USD |
| Open | 19.39 USD |
| Bid | 13.91 USD x 200 |
| Ask | 24.28 USD x 200 |
| Day's Range | 18.8 - 19.6 USD |
| 52 Week Range | 15.34 - 27.3 USD |
| Volume | 1.31M USD |
| Avg. Volume | 1.62M USD |
| Market Cap | 3.03B USD |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.19 USD |
DNLI Valuation Measures
| Enterprise Value | 2.68B USD |
| Trailing P/E | N/A |
| Forward P/E | -8.461821 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 141.60922 |
| Price/Book (mrq) | 3.2676005 |
| Enterprise Value/Revenue | 125.413 |
| Enterprise Value/EBITDA | -5.217 |
Trading Information
Denali Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.08 |
| 52-Week Change | 15.04% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 27.3 USD |
| 52 Week Low | 15.34 USD |
| 50-Day Moving Average | 19.93 USD |
| 200-Day Moving Average | 21.25 USD |
DNLI Share Statistics
| Avg. Volume (3 month) | 1.62M USD |
| Avg. Daily Volume (10-Days) | 1.84M USD |
| Shares Outstanding | 160.29M |
| Float | 155.54M |
| Short Ratio | 8.39 |
| % Held by Insiders | 4.59% |
| % Held by Institutions | 99.41% |
| Shares Short | 14.69M |
| Short % of Float | 9.66% |
| Short % of Shares Outstanding | 9.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2481.12% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.68% |
| Return on Equity (ttm) | -33.94% |
Income Statement
| Revenue (ttm) | 21.38M USD |
| Revenue Per Share (ttm) | 0.12 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -392201984 USD |
| EBITDA | -513996000 USD |
| Net Income Avi to Common (ttm) | -314423008 USD |
| Diluted EPS (ttm) | -1.72 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 516.2M USD |
| Total Cash Per Share (mrq) | 3.22 USD |
| Total Debt (mrq) | 35.24M USD |
| Total Debt/Equity (mrq) | 3.8 USD |
| Current Ratio (mrq) | 6.212 |
| Book Value Per Share (mrq) | 5.781 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -444187008 USD |
| Levered Free Cash Flow (ttm) | -301324256 USD |
Profile of Denali Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 161 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 866 8547 |
| Website | https://www.denalitherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 503 |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Q&A For Denali Therapeutics Stock
What is a current DNLI stock price?
Denali Therapeutics DNLI stock price today per share is 18.89 USD.
How to purchase Denali Therapeutics stock?
You can buy DNLI shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Denali Therapeutics?
The stock symbol or ticker of Denali Therapeutics is DNLI.
Which industry does the Denali Therapeutics company belong to?
The Denali Therapeutics industry is Biotechnology.
How many shares does Denali Therapeutics have in circulation?
The max supply of Denali Therapeutics shares is 160.29M.
What is Denali Therapeutics Price to Earnings Ratio (PE Ratio)?
Denali Therapeutics PE Ratio is now.
What was Denali Therapeutics earnings per share over the trailing 12 months (TTM)?
Denali Therapeutics EPS is -1.72 USD over the trailing 12 months.
Which sector does the Denali Therapeutics company belong to?
The Denali Therapeutics sector is Healthcare.
Denali Therapeutics DNLI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12491.48 USD — |
-0.35
|
— — | 12339.28 USD — | 12603.6 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7247.55 USD — |
-2.3
|
— — | 7246.35 USD — | 7373.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
